發(fā)布時間：2021-08-01 01:53

　　研究背景鼻咽癌（nasopharyngeal carcinoma,NPC）是一種特殊類型的頭頸部惡性腫瘤,原發(fā)于解剖部位隱蔽的鼻咽部。NPC的發(fā)病有其獨特的地理特點。NPC在東南亞,中國南方,尤其是廣東、廣西地區(qū),年發(fā)病率約為30/10萬,引發(fā)一系列嚴重的人群健康問題。而在美國或歐洲地區(qū),其年發(fā)病率小于1/10萬。NPC致癌過程是一個多步驟過程,目前發(fā)現NPC發(fā)病與EB病毒（Epstein-Barr virus,EBV）感染、遺傳易感性、環(huán)境致癌因素密切相關。目前,NPC的治療以放射治療為主。隨著調強放療技術的發(fā)展,早期NPC患者通過放療治療5年生存率可以達到80%以上。然而,大部分NPC患者在初診時已經處于中晚期,部分中晚期患者經過同步放化療治療后因腫瘤遠處轉移而治療失敗。因此,研發(fā)針對NPC的靶向藥物,對放療或化療有增敏作用的藥物,對提高中晚期NPC患者的療效有積極意義�？Х人岜揭阴ィ╟affeic acid phenethyl ester,CAPE）是一類多酚化合物。一些研究提示,CAPE具有抗癌,抗炎和免疫調節(jié)性質。其可以通過抑制腫瘤壞死因子（tumor necrosis fa... 

【文章來源】：廣西醫(yī)科大學廣西壯族自治區(qū)

【文章頁數】：173 頁

【學位級別】：博士

【部分圖文】：

CAPE的化學結構

圖 1-2：CAPE 單藥對于 4 株 NPC 細胞系 CNE2、CNE2EBV、HK1 和 HK1EBV 的細胞活Figure 1-2: Effect of CAPE on viability of nasopharyngeal carcinoma (NPC) cell lines. CNE2, CHK1 and HK1-EBV cells were treated with 1–80 μM CAPE for 24, 48, and 72 h and cell vievaluated by CCK8 assay. Data are mean ±SD of three independent experiment

單藥對于 4 株 NPC 細胞系 CNE2、CNE2EBV、HK1 和 HK1EBV 的ct of CAPE on viability of nasopharyngeal carcinoma (NPC) cell lines. CEBV cells were treated with 1–80 μM CAPE for 24, 48, and 72 h andK8 assay. Data are mean ±SD of three independent experiment

【參考文獻】：
期刊論文
[1]Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma[J]. Wen-Fei Li,Lei Chen,Ying Sun,Jun Ma.  Chinese Journal of Cancer. 2016(11)
[2]Epstein-Barr virus and nasopharyngeal carcinoma[J]. Lawrence S.Young,Christopher W.Dawson.  Chinese Journal of Cancer. 2014(12)
[3]A single nucleotide polymorphism in the matrix metalloproteinase 2 promoter is closely associated with high risk of nasopharyngeal carcinoma in Cantonese from southern China[J]. Ingemar Ernberg.  癌癥. 2011(09)
[4]The prevalence and prevention of nasopharyngeal carcinoma in China[J]. Malcolm J. Simons.  癌癥. 2011(02)
[5]Is nasopharyngeal cancer really a “Cantonese cancer”?[J]. Joseph Tien Seng Wee,Tam Cam Ha,Susan Li Er Loong.  癌癥. 2010(05)
[6]Effect of caffeic acid phenethyl ester on proliferation and apoptosis of colorectal cancer cells in vitro[J]. Dong Wang, De-Bing Xiang, Zeng-Peng Li, Xiao-Hua Wu, Jiang-Hong Mou, Hua-Liang Xiao, Qing-Hong Zhang, Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China Yu-Jun He, Department of General Surgery, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.  World Journal of Gastroenterology. 2005(26)



本文編號：3314606